Drug repositioning in pulmonary arterial hypertension: challenges and opportunities
Abstract
Despite many advances in medical therapy for pulmonary arterial hypertension (PAH) over the past 20 years, long‐term survival is still poor. Novel therapies which target the underlying pathology of PAH and which could be added to current vasodilatory therapies to halt disease progression and potentially reverse pulmonary vascular remodeling are highly sought after. Given the high attrition rates, substantial costs, and slow pace of new drug development, repositioning of “old” drugs is increasingly becoming an attractive path to identify novel treatment options, especially for a rare disease such as PAH.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 01, 2019
- Source ID
- 10.1177/2045894019832226
Entities
People
- Adam Andruska
- Bruce Bloom
- Cory Trankle
- Daniel Grinnan
- Edda Spiekerkoetter
Organizations
- Cures Within Reach
- National Center for Research Resources
- National Heart, Lung, and Blood Institute
- Pulmonary Hypertension Association
- Stanford University
- United States Department of Defense
- Virginia Commonwealth University